Contraceptive Special Issue

Filamentous actin disorganization and absence of apical ectoplasmic specialization disassembly during spermiation upon interference with retinoid signaling†

Sanny S. W. Chung1, Nika Vizcarra3 and Debra J. Wolgemuth1,2,3,4,*

1Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY, USA, 2Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA, 3The Institute of Human Nutrition Columbia University Irving Medical Center, New York, NY, USA and 4The Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA

*Correspondence: Department of Genetics & Development, Columbia University Irving Medical Center, Russ Berrie Pavilion, Room 608, 1150 St. Nicholas Avenue, New York, NY 10032, USA. Tel: (212) 851-4754; E-mail: djw3@cumc.columbia.edu

†Grant Support: This work was supported by National Institute of Child Health and Human Development Grants U01-HD060479 and U54-HD093540/P50-HD093540, project 1 (to D.J.W. and S.S.W.C.).

Disclosure Statement: The authors have nothing to disclose.

Received 3 March 2020; Revised 13 July 2020; Accepted 15 July 2020

Abstract

Spermiation is a multiple-step process involving profound cellular changes in both spermatids and Sertoli cells. We have observed spermiation defects, including abnormalities in spermatid orientation, translocation and release, in mice deficient in the retinoic acid receptor alpha (RARA) and upon treatment with a pan-RAR antagonist. To elucidate the role of retinoid signaling in regulating spermiation, we first characterized the time course of appearance of spermiogenic defects in response to treatment with the pan-RAR antagonist. The results revealed that defects in spermiation are indeed among the earliest abnormalities in spermatogenesis observed upon inhibition of retinoid signaling. Using fluorescent dye-conjugated phalloidin to label the ectoplasmic specialization (ES), we showed for the first time that these defects involved improper formation of filamentous actin (F-actin) bundles in step 8–9 spermatids and a failure of the actin-surrounded spermatids to move apically to the lumen and to disassemble the ES. The aberrant F-actin organization is associated with diminished nectin-3 expression in both RARA-deficient and pan-RAR antagonist-treated testes. An abnormal localization of both tyrosinated and detyrosinated tubulins was also observed during spermatid translocation in the seminiferous epithelium in drug-treated testes. These results highlight a crucial role of RAR receptor-mediated retinoid signaling in regulating microtubules and actin dynamics in the cytoskeleton rearrangements, required for proper spermiation. This is critical to understand in light of ongoing efforts to inhibit retinoid signaling as a novel approach for male contraception and may reveal spermiation components that could also be considered as new targets for male contraception.
Summary Sentence
A crucial role of RAR receptor-mediated retinoid signaling in regulating microtubule and actin dynamics in cytoskeleton rearrangements during spermiogenesis is demonstrated.

Key words: filamentous actin disorganization, apical ectoplasmic specialization disassembly, targets for male contraception.

Introduction
Mammalian spermatogenesis is a highly organized process with four key transitions: (i) differentiation of spermatogonia, (ii) meiotic initiation, (iii) initiation of spermiogenesis and spermatid elongation, and (iv) release of spermatids into the lumen of seminiferous tubules [1, 2]. During spermiogenesis, there is extensive chromatin remodeling and compaction, resulting in the highly condensed nuclei of spermatozoa, which are then released into the tubular lumen during spermatiation. Spermiation is a multiple-step process involving profound cellular changes in both spermatids and Sertoli cells, including translocation of spermatids from the adluminal to the luminal compartment, removal of specialized junctions, and eventual disengagement of the spermatids [3]. These processes are tightly associated with extensive changes in cellular shape and germ cell movement. The cytoskeleton, which comprises actin, microtubules and intermediate filaments, is believed to function in these cellular events [4–7]. During spermiogenesis, there is extensive restructuring of testis-specific heterotypic adherens junctions, known as the apical ectoplasmic specialization (apical ES) or the Sertoli-spermatid junction, at the interface between spermatids and Sertoli cells [4–6]. This restructuring is essential for the migration of developing spermatids across the epithelium so that fully developed spermatids can be released to the tubule lumen at spermatiation.

The apical ES is rich in hexagonal arrays of filamentous actin (F-actin) bundles sandwiched between the Sertoli cell plasma membrane and the endoplasmic reticulum. During spermiation, apical ES disassembly occurs—a gradual process that begins during late stage VII and involves reorganization of F-actin bundles into a highly branched network, which in turn facilitates spermatid movement and proper orientation [3]. Microtubules are also important components of the Sertoli cell cytoskeleton [4, 7]. A microtubule-directed mechanism has been suggested to also be involved in translocation of mature spermatids to the lumen [8]. Intratesticular injection of taxol, a microtubule stabilizer, led to the retention of rat step 19 spermatids deep within Sertoli cells crypts within 12–24 h, instead of their being transported toward the tubular lumen [8]. This suggested that microtubules also play an integral role in the spermatid translocation toward the tubular lumen.

It has been known for almost a century that signaling through vitamin A metabolites is indispensable for spermatogenesis [9–13]. Disruption of retinoic acid receptor alpha (RARA) function [13–17] and treatment with a pan-RAR antagonist [18, 19] resulted in male sterility and aberrant spermatogenesis, which resembled vitamin A deficiency (VAD) [20]. In particular, we have observed that spermiation in stage VII and VIII tubules is one of the physiological processes in spermatogenesis that is defective in all conditions of disrupted retinoid signaling including VAD, treatment with a pan-RAR antagonist, and disruption of RARA function. They include defects in the orientation of step 8–9 spermatids with regard to the basal aspect of Sertoli cells, a failure of spermatid alignment at the lumen in stage VIII tubules, and defects in spermiation [13, 15–20]. Interestingly, RARA mRNA and protein levels have been shown to be the highest at stage VIII in both germ cells and Sertoli cells [21, 22] and the levels of all-trans-retinoic acid (ATRA) are highest in these stages as well, as measured by HPLC analysis of synchronized tubules [23]. A recent study has further shown that ATRA plays primary roles at two postmeiotic transitions: the initiation of spermatid elongation and spermiation [24]. After injection of the inhibitor WIN18,446, both spermatid elongation and spermiation were delayed, and conversely, a single injection of RA was sufficient to precipociously induce both these transitions [24, 25]. However, neither the cellular nor molecular basis for this phenotype has been elucidated. Moreover, it is unknown what cellular structures involved in spermiation in the tubules are affected in the absence of RAR receptor-mediated retinoid signaling.

In the present study, we provide evidence for distinct functions of RAR-mediated retinoid signaling in regulating the changes in the cytoskeleton required for proper spermatiation. We demonstrate that defects in spermiation are among the earliest abnormalities in spermatogenesis upon pharmacologic inhibition of retinoid signaling. Further, F-actin disorganization and an absence of apical ES disassembly were observed as well as disruption of the proper cellular localization of tyrosinated and detyrosinated tubulins during spermatid translocation. These results revealed a critical role for RAR receptor-mediated retinoid signaling in regulating microtubule and actin dynamics during the cytoskeleton rearrangements, which in turn control proper spermiation, and hence, male fertility. Understanding the basic biology of cellular structures involved in defects in spermiation and their related cytoskeletal elements in Sertoli cells could also lead to the identification of new molecular targets for the development of male contraceptives.

Materials and Methods
Source of animals and tissue processing
The use of animals was approved by Columbia University Medical Center’s Animal Care and Use Committee. The generation of Rara−/− mice has been described previously [14]. CD1 mice (8 weeks, 30 g body weight) were obtained from Charles River Laboratories. Testes were dissected from anesthetized drug-treated 8-week-old CD1 mice at the specified time-points or from young adult (8 weeks) Rara−/− mice and weighed. One testis was fixed with 4% paraformaldehyde in 1x phosphate buffered saline (PBS) buffer and the second with Bouin’s fixative overnight at 4°C. Fixed tissues were embedded in paraffin or frozen in liquid nitrogen, sectioned at 5 μm, and mounted on Superfrost slides (Fisher) as previously described [17, 18, 26]. For staging of testicular tubules [2], sections were stained for the Periodic acid-Schiff reaction before hematoxylin counterstaining as previously reported [15, 16] and examined by bright-field microscopy. Rhodamine-conjugated peanut agglutinin (PNA) diluted in PBS was used to detect acrosomes in fluorescent staining (Vector Laboratories, RL-1072) as described previously [27, 28]. The staging of tubules was analyzed according to the criteria developed by Oakberg [1] and refined by Russell et al. [2]. The abnormal approximately staged tubules in Rara−/− and pan-RAR antagonist-treated seminiferous tubules have been
designated with a Roman numeral followed by an asterisk (e.g., stage IX*) as previously reported [15–19].

**Treatment of mice with a pan-RAR Antagonist, Compound 9**

Oral delivery of the drug to CD1 mice followed our previously described protocols [18, 26]. Briefly, the pan-RAR antagonist, Compound 9 (the commercially synthesized version of BMS-189453) [18], was suspended in a vehicle of aqueous 1.5% Avicel (CL-611, FMC BioPolymer) to obtain the desired concentrations and was administered to CD1 males (n = 5 each group) via oral gavage with a standard daily dose of 5 mg/kg/day for time periods as specified. Control groups (n = 5) received vehicle alone for 7 days. During the period of treatment, the mice were observed daily for changes in overall health and behavior as described previously [18, 19].

**Time course study**

To assess the effects on spermatiation during the course of the standard 7 day treatment regimen with the pan-RAR antagonist, 8-week-old mice (n = 5/time point) were treated with vehicle alone or at 5 mg/kg/day in vehicle by oral gavage and terminated 1 day after dosing periods of 1 to 7 days. To quantify the abnormalities within testicular tubules at the histological level, five males were used and 100–150 tubules per testis were analyzed. As described previously, only round-shaped tubules were assessed [15, 16]. Statistically significant differences were assessed using Student’s paired t-test using GraphPad Analysis software.

**Immunohistochemistry, immunofluorescence, and F-actin staining**

Paraffin and frozen sections of mouse testes were immunostained using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) as previously described [17, 29]. The following primary antibodies were used: rat monoclonal Anti-nectin 3 (1:50, #103-A1, Hyctul Biotech, Netherlands); mouse monoclonal anti-tyrosinated tubulin (1:1000, TUB-1A2, Sigma Aldrich) and rabbit polyclonal anti-detyrosinated tubulin (also referred to as glu-tubulin, reflecting the newly exposed C-terminal glutamate residue) [1:400; gift from the Gundersen Lab at Columbia University] [30, 31]. For controls, the slides were incubated with the appropriate immunoglobulin G (IgG) or pre-immune serum instead of primary antibody. For comparison of the relative levels of expression between samples, caution was made to minimize the variation in fixation, thickness of sections, etc. by for example, samples being processed at the same time and obtaining standard 5 µm-thickness for the sections. In addition, sectioned tissues from different experimental groups (for example, control versus drug-treated, etc.) were collected onto a single slide to enable relative quantitative comparisons with greater confidence [16, 32]. The sections were viewed on a Nikon photomicroscope under bright-field optics.

For immunofluorescence, slides were blocked with universal blocking solution (CAS-Block, Invitrogen) for 30 min. The secondary antibodies used were diluted to 1:200 in CAS-Block: Alexa 488-conjugated goat anti-mouse IgG (H + L) (Invitrogen, A-11029), and Alexa 647-conjugated donkey anti-rabbit IgG (H + L) (Jackson ImmunoResearch, 711–605-152). Rhodamine-conjugated PNA at 1:2000 dilution in PBS was used to detect acrosomes (Vector Laboratories, RL-1072) as described previously [19, 27, 28] counterstained with DAPI, and mounted with Glycergel mounting medium. Slides were then viewed on a Nikon photomicroscope under fluorescence optics. Fluorescent images were captured using a confocal Zeiss LSM710 microscope as described previously [33, 34]. Z stacks, composed of 0.25-µm optical sections, were obtained using the Zen 2011 software (Zeiss). Images were subsequently analyzed and processed using the public domain software ImageJ (NIH).

**Results**

**Defects in spermatiation upon inhibition of retinoid signaling**

We had previously reported the observation of spermatiation defects, including defects in spermatid orientation, translocation and release, in both RARA-deficient [14–16] and pan-RAR antagonist-treated models [18, 19]. To detect how soon we observed the defects after administration of the pan-RAR antagonist, we examined systematically the effects on spermatiation during the course of the standard 7-day treatment regimen. Specifically, 8-week-old mice (n = 5/time point) were treated at 5 mg/kg/day and euthanized at different time points during the dosing period. To quantify the abnormalities within testicular tubules at the histological level, three to five males were used and 100–150 tubules per testis were analyzed. Interestingly, as compared to control (Figure 1A), we found that defects in spermatiation (Figure 1B–D) are indeed among the earliest abnormalities in spermatogenesis observed in response to treatment with the pan-antagonist (Figure 1E). To address which aspects of spermatiation, whether a failure of spermatid translocation or a failure of spermatid release, were first induced in response to treatment, we examined carefully the testes after 3, 4, and 7 days of drug treatment. Strikingly, a failure of step 16 spermatid release or spermatid disengagement (the final stage of spermatiation) was observed as early as 3 days of treatment with the pan-antagonist (Figure 1B). After 4 days of pan-antagonist treatment, both failure of spermatid translocation and release were observed in drug-treated testes (Figure 1C), and after 7 days of pan-antagonist treatment, both failure of spermatid
translocation and release were consistently observed (Figure 1D). This suggests that at day 3 post treatment, although the early proper alignment of step 16 elongated spermatids at the tubular lumen of stage VIII tubules was seen, they fail to disengage at spermiation.

Filamentous actin (F-actin) disorganization and failure of apical ES disassembly

Given the important role of F-actin in proper spermiogenesis [3–7], we wished to determine whether abnormalities in formation of F-actin bundles might be involved in both pan-RAR-treated and Rara−/− testes. We therefore used staining with AF488-conjugated phalloidin (green) to visualize the structures in control versus the experimental testes. In control mouse testes, we observed a stage-specific, spatial localization of F-actin bundles at the apical ES between elongating spermatids and Sertoli cells in the seminiferous tubules (Supplementary Figure S1A–H and Figure 2A, B, and G), consistent with observations reported by others [35]. Specifically, F-actin bundles were first detected in step 9 spermatid heads at stage IX in a crescent overlying the convex aspect of the acrosomal region (steps 9–12) (Supplementary Figure S1G; and at higher magnification, Figure 2A and B) and later surround the closely clustered step 13–15 spermatids deep in crypts of the Sertoli cells at stages I–V (Supplementary Figure S1A–C). During spermiation, F-actin bundles are located along the luminal surface in late elongated spermatids (step 16; stages VII and VIII), which have been translocated to the adluminal compartment (Supplementary Figure S1D and F; Figure 2G). F-actin was no longer detectable at Sertoli-spermatid junctions at the end of stage VIII, after apical ES disassembly to permit disengagement of spermatids (Supplementary Figure S1F).

In both pan-antagonist-treated (Figure 2C–E, H) and Rara−/− (Supplementary Figure S2C–F) testes, F-actin was abnormally distributed and bundles failed to form at the apical ES. For example, in contrast to the localization of F-actin in a crescent overlying the convex aspect of the acrosomal region as shown in control testes (Figure 2A and B), there was no localization of F-actin at the apical ES of step 9 spermatids (Figure 2C and D, red bracket), indicating the apical ES was not properly established at the interface between the elongating spermatids and Sertoli cells. Interestingly, F-actin was found surrounding the abnormally retained condensed elongating spermatids at stage IX, suggesting that apical ES disassembly does not occur (Figure 2C–F, yellow arrows). This suggested a distinct effect of the pan-RAR antagonist on overall F-actin dynamics; that is, it appears to block formation of new ES junctions and block disassembly of ES junctions on elongated spermatids (yellow arrows). In addition, we observed F-actin surrounding aberrantly retained spermatids at stage VIII* (Figure 2H, yellow arrows), as compared to the F-actin bundles located along the luminal surface in late condensing stage 16 spermatids that had translocated from the adluminal compartment in control testes (Figure 2G).

F-actin disorganization is associated with diminished nectin-3 expression in Rara−/− testes and pan-antagonist-treated testes

It has been shown that two major adhesion molecules in the testes, nectin-2 in Sertoli cells and nectin-3 in spermatids, together with the adaptor protein afadin, co-localize with F-actin at apical ES junctions [35]. In nectin-2 null testes, spermatids were randomly distributed within the tubules, with abnormally positioned afadin and F-actin bundles, suggesting defects in the apical ES [35]. Further, F-actin was disorganized and nectin-2 was absent in nectin-3 null testes indicating that the presence of nectin-3 is essential for the localization of nectin-2 at apical ES as well [36].

We first confirmed the reported stage-specific co-localization of nectin-3 and F-actin at the apical ES in control testes [35] (Supplementary Figure S3A and B). F-actin (green) and nectin-3 (red) co-localize in step-9 spermatid heads at stage IX (Supplementary Figure S3B). During spermiation, at stage VII, the step 16 condensing spermatids are translocated to the luminal surface of the seminiferous tubules. Nectin co-localized with F-actin at apical ES of the step 16 spermatids, which were aligned at the luminal surface of the stage VII tubules (Supplementary Figure S3A). In Rara−/− testes (Supplementary Figure S3C and D), however, the detection of nectin-3 was reduced or absent in the elongating spermatids (step 9–11 spermatids) at stages IX*–XI* (Supplementary Figure S3D, red brackets), as compared to control (Supplementary Figure S3B). The lack of nectin-3 expression became more prominent during spermiation. At stage VII, absence of nectin-3 expression was found in retained elongated spermatids (yellow arrows in Supplementary Figure S3C), which were located adluminally rather than aligning at the tubular lumen. Interestingly, we detected downregulation of nectin-3 in concomitant preliminary microarray analysis of Rara−/− testes (data not shown).

We next examined whether levels of nectin-3 were also down-regulated in the pan-RAR antagonist-treated testes as assessed by immunohistochemistry. Indeed, as compared to control (Figure 3A), the detection of nectin-3 was reduced in elongating spermatids (step 9–11, stages IX*–XI*) after 3 days of treatment (Figure 3B, red arrows) and by 7 days after treatment, most elongating spermatids lacked detectable nectin-3 expression (Figure 3C, red brackets). Downregulation of nectin-3 expression was consistently found during early stages of spermiation (Stages VII* and VIII*, Figure 3E and F) as compared to control (Figure 3D). Three days after drug treatment, an absence of nectin-3 expression was found in most of the condensing elongated spermatids in stage VII tubules, although these elongated spermatids were properly translocated to the adluminal compartment and were aligned at the luminal surface of the tubules (red arrows in Figure 3E). By 7 days after treatment, at stage VII* to VIII*, nectin-3 expression was not detected in either retained (Figure 3F, yellow arrow) or translocated (Figure 3F, red arrow) elongated spermatids in stage VII* and VIII* tubules. Therefore, pan-RAR antagonist-induced spermatid retention is associated with diminished nectin-3 at the Sertoli-spermatid junctions and with F-actin disorganization.

Abundant tyrosinated tubulin surrounding the aberrantly retained spermatids at stages VII*–IX* in Rara−/− testes and pan-RAR antagonist-treated testes

Mature spermatids are thought to be translocated to the lumen by Sertoli cells via the movement of junction plaques along a microtubule tract by minus-end-directed dynactin motor proteins [37–40]. We hypothesized that retinoid signaling could affect microtubule dynamics, specifically involving alteration of the levels of tyrosinated tubulin, which is highly expressed during tubulin polymerization, and detyrosinated tubulin, which is found in stabilized microtubules and shown to be important for anchoring elongating spermatids into the deep crypts of Sertoli cells at stages IX–XII [31, 41, 42].

We first asked if there was a stage-specific and restricted spatial localization of tyrosinated tubulin in mouse testes, similar to that described in rats [43] (Figure 4A and B). At stage IX-stage I,
branched localization of tyrosinated tubulin was observed surrounding pachytenic spermatocytes (Figure 4A; Supplementary Figure S4A). Tyrosinated tubulin also surrounded elongating spermatid heads (step 9–12) in a crescent overlying the convex aspect of the acrosomal region, which allows the establishment of microtubules (tubulin polymerization). Once condensing spermatids (step 14–15; stages II–VI) were in the crypts of Sertoli cells, tyrosinated tubulin became condensed into a spoke-like pattern (Figure 4A and B; Supplementary Figure S4B), indicating active tubulin polymerization, which is critical for spermatid translocation and spermiation. During stages VII and VIII, when spermatids are translocated to the luminal surface, the spoke-like pattern of tyrosinated tubulin was weakly and sparsely detected (Figure 4B, bracket; Supplementary Figure S5A). This reduced tubulin polymerization (reflected by reduced tyrosinated tubulin) was observed at stages VII and VIII, when the spermatids have already been translocated to luminal surface and the microtubule tracts are no longer needed.

In testes of mice treated with the pan-RAR antagonist, tyrosinated tubulin was ectopically localized around the aberrantly retained elongated spermatids at stage VIII* and IX* tubules (Figure 4C–E, arrow; Supplementary Figure S5B), which was never seen in control step 16 spermatids (Figure 4B, bracket). A similar pattern of ectopic localization of tyrosinated tubulin was seen in the Rara−/− testes (Figure 4F, arrow), with tyrosinated tubulin surrounding the retained late condensing elongated spermatids at stages VIII* and IX*. This suggested that elongated spermatids were
confirmed with confocal microscopy (Supplementary Figure S4A). A condensed, spoke-like pattern of detyrosinated tubulin was found as a bundle in Sertoli cells surrounding leptotene, zygotene, and diplotene spermatocytes from stage IX to XII and pachytene spermatocytes from stage IX-I (Figure 5A–C; Figure 6A, red). At stage I, there was robust detyrosinated tubulin expression surrounding step 13 condensing spermatids (Figure 5A and B, Figure 6A, red), indicating that tubulin polymerization was stabilized so as to anchor condensing spermatids into the crypts of Sertoli cells. Interestingly, once the spermatids (step 14–15; stages II–VI) are clustered together, detyrosinated tubulin (normally detected in stabilized microtubules) was no longer detected in a spoke-like pattern around step 14–15 spermatids nor around step 16 spermatids and was very weak (bracket, stage VIII, Figure 5C and D; Figure 6A, red; Supplementary Figure S5A). It was, however, detected surrounding step 2–8 round spermatids during stages II–VIII (Figure 5B–D; Figure 6A, red). Interestingly, this localization is in contrast to tyrosinated tubulins: once the condensing spermatids (step 14–15; stages II–VI) are clustered together, tyrosinated tubulin was strongly expressed (Figure 4A and B, Figure 6A, green; Supplementary Figure S4B). Before and during spermatiation, the spoke-like pattern of detyrosinated tubulin was barely detectable around step 16 spermatids at stages VII and VIII (Figure 5C and D, inset in Figure 5D).

In pan-RAR antagonist-treated testes, detyrosinated tubulin was ectopically localized around the aberrantly retained late elongated spermatids at the basal region in stages VII–IX* tubules (Figure 5E and F, arrow; Figure 6B, red). This observation was also confirmed with confocal microscopy (Supplementary Figure S5B) and is quite different from the complete lack of detyrosinated tubulin distribution surrounding step 16 spermatids in the control testes (Figure 5D). Since detyrosinated tubulin is found in stabilized microtubules, we suggest that these retained elongated spermatids failed to translocate during stages VII* and VIII* because of its persistent presence. Interestingly, the retained spermatids with abundant detyrosinated tubulin were only observed in the pan-antagonist-treated testes, but not in the retained spermatids in Rara−/−, stages IX* tubules (Figure 5G and H, arrow).

Discussion

We have previously shown that Rara−/− testes and pan-RAR antagonist-treated testes exhibit failure of spermatid alignment and sperm release. In the present study, we extended this observation to a more mechanistic level, illustrating distinct functions of RAR-mediated retinoid signaling in regulating microtubule and actin dynamics during the cytoskeleton rearrangements that are required for proper spermatiation. We first characterized the time course of appearance of spermiogenic defects in response to treatment with the pan-RAR antagonist. The results revealed that defects in spermatiation, especially in release of spermatids, are indeed one of the earliest abnormalities in spermatogenesis observed upon inhibition of retinoid signaling. This is similar to spermatiation failure induced by gonadotrophin suppression model [44], in which spermatiation failure occurs as a result of a defect in the final release or disengagement of spermatids, and not defects in earlier spermatiation processes [44]. The proteins that maintain the spermatid and the Sertoli cell junctions until the point of disengagement have been suggested to be one of the critical candidates in regulating sperm release [3]. These proteins

Figure 2. Aberrant location of F-actin surrounding the retained late elongated spermatids at stage IX and VIII tubules of pan-RAR antagonist-treated testes. (A–H): Histological sections of testes from 8-week-old adult control (A, B, G) and pan-antagonist-treated (C–F, H) mice with 5 mg/kg for 7 days and examined one-day after treatment. The F-actin bundles of the ES are labeled with fluorescent dye-conjugated phalloidin (green) and counterstained with nuclear DAPI (blue). (A–H): Original magnification, ×60. (A–D, G and H): Merged image of F-actin and DAPI and (E and F): DAPI staining showed the same tubule in (C), respectively, for displaying retained spermatids. Arabic numerals indicate the step of spermatid differentiation. Roman numerals indicate the stage of the tubules. Abnormal tubules are labeled with a Roman numeral followed by an asterisk (e.g., stage IX*). The yellow arrows in (C, E, and F) point to the abnormally retained elongated spermatids while the red bracket in (C) and (D) indicates step 9 spermatids. (B, D, F) are the magnified inset of (A, C, E), respectively. Scale bar in (A, C, E, G, and H), 50 µm; scale bar in inset (B, D, F), 80 µm.

retained in the adluminal compartment and were not translocated along the microtubule tracks to the luminal surface for spermatiation, leading to persistence of tyrosinated tubulin at stage VIII* tubules in Rara−/− testes (Figure 4F), as compared to control (Figure 4B, stage VIII tubule).

Abundant detyrosinated tubulin surrounds retained spermatids in testes with disrupted retinoid signaling

In control testes, detyrosinated tubulin (reflecting stabilized microtubules) was detected from stage IX to XII, surrounding elongating spermatid heads (step 9–12) predominantly within the manchette region (Figure 5A–C, Figure 6A, red), which was
include adhesion-related proteins such as α6β1 integrin and galectin 1, signaling proteins (including phosphorylated FAK, SRC, CDC42, CSK, Pten, PI3K, and ERK) and proteases, such as MT-MMP1 and MMP2 [3]. Interestingly, in studies on adjuin functions, sperm release at spermiation was reported to be regulated by changes in the organization of actin and microtubule-based cytoskeletons at the apical ES [45] and regulation of spermatid polarity by the actin- and microtubule-based cytoskeletons was also suggested [46]. Understanding the basic biology of cytoskeletal structures involved in defects in spermiation not only provides insight into the underlying causes of male infertility but could also lead to the identification of new molecular targets for development of male contraceptives.

Among the more striking sub-cellular aspects of the spermiation defects exhibited by the knockout and pan-RAR antagonist models were the F-actin disorganization and an absence of apical ES disassembly (summarized in the cartoon in Figure 6). Apical ES disassembly is indeed a crucial step during spermiation. In particular, in early stage VIII, actin-binding proteins (e.g., EPS8 and palladin) are downregulated while actin-branching proteins (the ARP2/3 complex) are induced [3–6]. As such, F-actin changes from a bundled to branched configuration and destabilizes the adhesion protein complexes. In addition, it has been reported that the nonreceptor protein tyrosine kinases (e.g., c-YES and c-SRC) also facilitate endocytic vesicle-mediated protein trafficking (endocytosis, transcytosis, and/or recycling) [3–6]. The recycling and/or endosome-mediated degradation of integral membrane proteins at the apical ES further destabilizes spermatid adhesion, facilitating the release of sperm at spermiation. We believed these candidates and their signaling pathways will also provide insight into the role of retinoid signaling during spermiation and will suggest new targets for contraceptive validation.
Our current study also revealed that the aberrant F-actin organization is associated with diminished nectin-3 expression in both Rara−/− and pan-RAR antagonist-treated testes. As such, the down-regulation of nectin-3 may affect the proper formation and/or maintenance of the actin scaffold at apical ES. Similar to what we have observed in Rara−/− and pan-RAR antagonist-treated testes, the apical ES of step 9 and 10 nectin-2-deficient elongating spermatids often lacked F-actin bundles. Afadin, which co-localizes with F-actin at apical ES, was also found to be absent in apical ES junction of nectin-2 null testes suggesting that nectin-2 recruits and/or maintains F-actin bundles at apical ES through afadin [35]. Nectin-3, on the other hand, is essential for the localization of nectin-2 at apical ES, as suggested by the observation that nectin-2 was absent and the F-actin was disorganized in nectin-3 null testes [36]. In support of the critical roles of the cytoskeletal elements in proper F-actin bundles at the apical ES during normal spermiogenesis, it should be recalled that, similar to nectin-2 and nectin-3, disorganization of the actin cytoskeleton was also observed in junctional adhesion molecule-C (JAM-C)–deficient male mice, which exhibited male-specific infertility as well [47].

It has also been reported that changes in the phosphorylation status of tubulin can result in a failure to undergo spermiation [3]. Using an in vitro tubule culture system, it has been reported that the release of spermatids from cultured stage VIII tubules decreased when serine/threonine kinase activity was inhibited, yet was increased with the addition of okadaic acid, a serine/threonine phosphatase inhibitor [48]. Consistent with this, antibodies against phosphorylated serine, threonine and tyrosine proteins immunostain the Sertoli cell–spermatid junction during spermiation [48, 49]. Immunoprecipitation studies on protein interactions before and after
Figure 5. Aberrantly retained spermatids surrounded with detyrosinated tubulin at stage VII\textsuperscript{*}–IX\textsuperscript{*} tubules in pan-RAR antagonist-treated testes. (A–H): Histological sections of testes from 8-week-old adult control (A–D), pan-RAR antagonist-treated (E, F) mice with 5 mg/kg for 7 days and examined one-day after treatment, and Rara\textsuperscript{−/−} (G, H) testes. Sections were stained with an anti-detyrosinated tubulin antibody to label tubulin polymerization. Original magnification, ×40. The arrows in (E) and (F) point to retained spermatids with detyrosinated tubulin, but not in (G) and (H). The brackets in (C) and (D) show that the staining on normal spermatids at stage VIII was very weak. Pl, Preleptotene spermatocytes; L, leptotene spermatocytes; Z, zygotene spermatocytes; P, pachytene spermatocytes. The Arabic numerals indicate the step of spermatid differentiation. The Roman numerals indicate the stage of the seminiferous tubules. Although abnormal cell associations complicate staging, an attempt was made to stage the pan-RAR antagonist-treated tubules using acrosomal system, and tubules are labeled with a Roman numeral followed by an asterisk (e.g., stage IX\textsuperscript{*}). The inserts in (D, F) and (G) displayed the enlarged magnification of the corresponding figures. Scale bar, 50 µm.
Figure 6. A cartoon illustrating the changes in cellular localization of tyrosinated (green) and detyrosinated (red) tubulins and actin dynamics during spermatid translocation in the seminiferous epithelium of normal (A) and drug-treated testes (B).

Spermatid disengagement suggest that ERK phosphorylation and 14-3-3 signaling may play important roles in spermatid release [48]. Lastly, phosphorylation of various adhesion molecules has been shown to be involved with spermiation [3, 48–51]. One of the most common posttranslational modifications is phosphorylation and indeed, phosphorylation of specific sperm proteins is an important event necessary to achieve fertilization [52].

We demonstrated in this study an abnormal localization of both tyrosinated and detyrosinated tubulins surrounding the retained spermatids in the seminiferous epithelium upon interference with retinoid signaling (Figure 6). Microtubule dynamics, specifically involved alteration of the levels of tyrosinated tubulin, which is highly expressed during tubulin polymerization, and detyrosinated tubulin, which is found in stabilized microtubules and shown to be important for anchoring elongating spermatids into the deep crypts of Sertoli cells at stages IX–XII. It has been suggested that the localization of tyrosinated tubulin in a crescent overlying the convex aspect of the acrosomal region of step 9–12 elongating spermatid heads was to allow the establishment of microtubules (tubulin polymerization) [43]. Once step 14–15 condensing spermatids at stages II–VI were in the crypts of Sertoli cells, tyrosinated tubulin became condensed into a spoke-like pattern, indicating active tubulin polymerization and establishment of microtubules to support the apical ES between the spermatids and Sertoli cells [43]. This is critical because it takes part in the relative arrangement of actin and microtubule cytoskeleton for spermatid translocation and
spermiation. During stages VII–VIII, the spoke-like pattern of tyrosinated tubulin was weakly and sparsely detected, reflecting the fact that the spermatids have already been translocated to the luminal surface and the microtubule tracts are no longer needed. In contrast, in the absence of retinoid signaling, spermatids were not translocated and remained in Sertoli cell crypts, concomitant with the persistence of microtubule tract polymerization (Figure 6). Our observation of the presence of tyrosinated tubulins surrounding the retained spermatids was consistent with the notion that spermatid translocation from the adluminal to the luminal compartment does not occur in Rara–/– gests and pan-RAR antagonist-treated testes. Thus, retinoid signaling-induced changes in tubulin dynamics may play a role in defects during spermatid translocation toward the lumen. A recent finding demonstrating that dynein 1 supports spermatid transport and spermiation during spermatogenesis in the rat testis, using RNAi to knockdown cytoplasmic dynein 1 heavy chain and an inhibitor ciliobrevin D [40], suggests that it would be interesting to determine whether dynein is also affected upon inhibition of retinoid signaling.

In conclusion, we note that it is of interest that retained spermatids with detyrosinated tubulin were observed in the pan-RAR antagonist-treated testes, but not in the retained spermatids in Rara–/– stage IX+ tubules. This observation may indicate that long-term effects of RARA deficiency are associated with an absence of detyrosinated tubulin surrounding retained spermatids as well as with a difference in tubulin defects between acute and chronic lack of retinoic acid signaling. Retinoid signaling-induced changes in tubulin dynamics thus appear to play a role during spermatid translocation toward the lumen and spermatid release and proteins involved in this process may constitute new targets for male contraception.

Supplementary data

Supplementary data is available at BIOLRE online.

Acknowledgements

The authors would like to thank Dr. Xiangyuan Wang for preparing histological sections and performing the gavage administration of drug to mice and Dr. Marcia Manterola for providing expert technical advice on the use of confocal microscopy.

Conflict of Interest

The authors have declared that no conflict of interest exists.

Author Contributions

S.S.W.C. and D.J.W. conceived and designed the experiments; S.S.W.C. and N.V. performed the experiments; S.S.W.C., N.V., and D.J.W. contributed reagents/materials/analysis tools. S.S.W.C. and D.J.W. analyzed the data and wrote the paper.

References

1. Oakberg EF. A description of spermiogenesis in the mouse and its use in analysis of the cycle of the seminiferous epithelium and germ cell renewal. 
   *Am J Anat* 1936; 98:391–413.

2. Russell LD, Ettlin RA, SinhaHikim AP, Clegg ED. *Histological and Histopathological Evaluation of the Testis*. Clearwater, FL: Cache River Press; 1990.

3. O’Donnell L, Nicholls PK, O’Byrne MK, McLachlan RI, Stanton PG. Spermiation: The process of sperm release. *Spermatogenesis* 2011; 1:14–35.

4. Lie PP, Mruk DD, Lee WM, Cheng CY. Cytoskeletal dynamics and spermatogenesis. *Philos Trans R Soc Lond B Biol Sci* 2010; 365:1581–1592.

5. Xiao X, Mruk DD, Wong CK, Cheng CY. Germ cell transport across the seminiferous epithelium during spermatogenesis. *Physiology (Bethesda)* 2014; 29:286–298.

6. Qian X, Mruk DD, Cheng YH, Tang El, Han D, Lee WM, Wong FW, Cheng CY. Actin binding proteins, spermatid transport and spermiation. *Semin Cell Dev Biol* 2014; 30:75–85.

7. Vogl AW, Vaid KS, Gutman JA. The Sertoli cell cytoskeleton. *Adv Exp Med Biol* 2008; 636:186–211.

8. Russell LD, Saxena NK, Turner TT. Cytoskeletal involvement in spermiation and sperm transport. *Tissue Cell* 1989; 21:361–379.

9. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. *J Exp Med* 1925; 42:753–777.

10. Howell JM, Thompson JN, Pitt GAJ. Cytoskeletal involvement in spermatogenesis. *Histochemistry* 1994; 531–559.

11. Eskild W, Hansson V. Vitamin A functions in the reproductive organs. In: Blomhoff R (ed.), *Vitamin A in Health and Disease*. New York: Dekker; 1994: 551–559.

12. Packer AI, Wolgemuth DJ. Genetic and molecular approaches to understanding the role of retinooids in mammalian spermatogenesis. In: Nau H, Blaner WS (eds.), *Retinoic Acid: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action*. Berlin Heidelberg New York: Springer-Verlag; 1999: 347–368.

13. Chung SS, Wolgemuth DJ. Role of retinoid signaling in the regulation of spermatogenesis. *Cyagenet Genome Res* 2004; 105:189–202.

14. Luftin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. *Proc Natl Acad Sci U S A* 1993; 90:7225–7229.

15. Chung SS, Sung W, Wang X, Wolgemuth DJ. Retinoic acid receptor alpha is required for synchronization of spermatogenic cycles and its absence results in progressive breakdown of the spermatogenic process. *Dev Dyn* 2004; 230:754–766.

16. Chung SS, Wang X, Wolgemuth DJ. Male sterility in mice lacking retinoic acid receptor alpha involves specific abnormalities in spermiogenesis. *Differentiation* 2005; 73:188–198.

17. Chung SS, Wang X, Wolgemuth DJ. Expression of retinoic acid receptor alpha in the germ line is essential for proper cellular association and spermiation during spermatogenesis. *Development* 2009; 136:2091–2100.

18. Chung SS, Wang X, Roberts SS, Griffey SM, Reczek PR, Wolgemuth DJ. Oral administration of a retinoic acid receptor antagonist reversibly inhibits spermatogenesis in mice. *Endocrinology* 2011; 152:2492–2502.

19. Chung SS, Wang X, Wolgemuth DJ. Prolonged oral administration of a pan-retinoic acid receptor antagonist inhibits spermatogenesis in mice with a rapid recovery and changes in the expression of influx and efflux transporters. *Endocrinology* 2016; 157:1601–1612.

20. Huang HF, Marshall GR. Failure of spermatid release under various vitamin A states - an indication of delayed spermiation. *Biol Reprod* 1983; 28:1163–1172.

21. Akmal KM, Dufour JM, Kim KH. Retinoic acid receptor alpha gene expression in the rat testis: Potential role during the prophase of meiosis and in the transition from round to elongating spermatids. *Biol Reprod* 1997; 56:549–556.

22. Dufour JM, Kim KH. Cellular and subcellular localization of six retinoid receptors in rat testis during postnatal development: Identification of potential homodimeric receptors. *Biol Reprod* 1999; 61:1300–1308.
23. Hogarth CA, Arnold S, Kent T, Mitchell D, Isoherranen N, Griswold MD. Procesive pulses of retinoic acid propel asynchronous and continuous sperm production. *Biol Reprod* 2015; 92:37.

24. Endo T, Freinkman E, de Rooij DG, Page DC. Periodic production of retinoic acid by meiotic and somatic cells coordinates four transitions in mouse spermatogenesis. *Proc Natl Acad Sci U S A* 2017; 114:E10132–E10141.

25. Endo T, Midedis MM, Nicholls PK, Page DC, de Rooij DG. Retinoic acid and germ cell development in the ovary and testis. *Biomolecules* 2019; 9:775.

26. Chung SS, Cuellar RA, Wang X, Reczek PR, Georg GI, Wolgemuth DJ. Pharmacological activity of retinoic acid receptor alpha-selective antagonists in vitro and in vivo. *ACS Med Chem Lett* 2013; 4:446–450.

27. Maser B, Medrano S, Sleight SB, Visconti PE, Scrobble H. Developmental association of the synaptic activity-regulated protein arc with the mouse acrosomal organelle and the sperm tail. *Biol Reprod* 2003; 68:67–76.

28. Morimoto H, Kanatsu-Shinohara M, Takashima S, Chuma S, Nakatsuji N, Takehashi M, Shinohara T. Phenotypic plasticity of mouse spermatogonial stem cells. *PLoS One* 2009; 4:e7909.

29. Liu D, Matzuk MM, Sung WK, Guo Q, Wang P, Wolgemuth DJ. Cyclin A1 is required for meiosis in the male mouse. *Nat Genet* 1998; 20:377–380.

30. Gundersen GG, Kalinoski MH, Bulinski JC. Distinct populations of microtubules: Tyrosinated and nontyrosinated alpha tubulin are distributed differently in vivo. *Cell* 1984; 38:779–789.

31. Gurland G, Gundersen GG. Stable, detyrosinated microtubules function to localize vimentin intermediate filaments in fibroblasts. *J Cell Biol* 1995; 131:1275–1290.

32. Mutter GL, Grills GS, Wolgemuth DJ. Evidence for the involvement of the microtubule-dependent motors cytoplasmic dynein and kinesin in spermatid translocation (dynein) and spermatid flagella (kinesin-II). *Biol Reprod* 1999; 60:1047–1056.

33. Hall ES, Eveleth J, Jiang C, Redenbach DM, Boekelheide K. Distribution of the microtubule-dependent motors cytoplasmic dynein and kinesin in rat testis. *Biol Reprod* 1992; 46:817–828.

34. Manterola M, Sicinski P, Wolgemuth DJ. E-type cyclins modulate telomere integrity in mammalian male meiosis. *Chromosoma* 2016; 125:253–264.

35. Guttman JA, Kimel GH, Vogl AW. Dynein and plus-end microtubule-dependent motors are associated with specialized Sertoli cell junction plaques (ectoplasmic specializations). *J Cell Sci* 2000; 113:2167–2176.

36. Wen Q, Tang ET, Lui WY, Lee WM, Wong CKC, Silvestrini B, Cheng CY. Dynemin I supports spermatid transport and spermiogenesis during spermatogenesis in the rat testis. *Am J Physiol Endocrinol Metab* 2018; 315:E924–E948.

37. Miller MG, Mulholland DJ, Vogl AW. Rat testis motor proteins associated with spermatid translocation (dynein) and spermatid flagella (kinesin-II). *Biol Reprod* 2017; 92:E10141.

38. Hall ES, Eveleth J, Jiang C, Redenbach DM, Boekelheide K. Distribution of the microtubule-dependent motors cytoplasmic dynein and kinesin in rat testis. *Biol Reprod* 1992; 46:817–828.